Association between cumulative incidence of relapse at 3 years and early reverse transcriptase–polymerase chain reaction result according to different clinical variables
| RT-PCR result . | Total patients, % . | Type of donor, % . | GVHD prophylaxis, % . | Disease stage, % . | |||
|---|---|---|---|---|---|---|---|
| SIB . | URD . | TCD . | Non-TCD . | CP . | AP . | ||
| Negative | 16.7 | 10.5 | 25 | 26.4 | 6.2 | 14.8 | 28.7 |
| Low-level positive | 42.9 | 28.6 | 57 | 62.5 | 16.7 | 50 | 3-150 |
| High-level positive | 86.4 | 70.6 | 95 | 95.3 | 64.7 | 84.5 | 90.9 |
| RT-PCR result . | Total patients, % . | Type of donor, % . | GVHD prophylaxis, % . | Disease stage, % . | |||
|---|---|---|---|---|---|---|---|
| SIB . | URD . | TCD . | Non-TCD . | CP . | AP . | ||
| Negative | 16.7 | 10.5 | 25 | 26.4 | 6.2 | 14.8 | 28.7 |
| Low-level positive | 42.9 | 28.6 | 57 | 62.5 | 16.7 | 50 | 3-150 |
| High-level positive | 86.4 | 70.6 | 95 | 95.3 | 64.7 | 84.5 | 90.9 |
Cumulative incidence of relapse is expressed as probability (%) at 3 years after SCT.
CP indicates chronic phase; AP, accelerated phase; for other abbreviations, see Tables 1 and 2.
Indicates less than 5 patients.